Literature DB >> 21350868

[Janus-faced?: Effects and side-effects of interferon therapy in ophthalmology].

N Stübiger1, S Winterhalter, U Pleyer, D Doycheva, M Zierhut, C Deuter.   

Abstract

Interferon alpha (IFN-α) and interferon beta (IFN-β) are naturally occurring cytokines, which belong to the type I interferons and share the same receptor leading to very similar therapeutic effects. The immunomodulatory effect of type I interferons includes modulation of antibody production, inhibition of lymphocyte proliferation, inhibition of delayed-type hypersensitivity and enhancement of T-cell and NK-cell cytotoxicity. An increasing number of open clinical studies and case reports have demonstrated the efficacy of IFN-α for severe ocular inflammation in patients with Behçet's disease and of interferon-β, which has been used mainly for the treatment of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21350868     DOI: 10.1007/s00347-010-2261-1

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  47 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

2.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

4.  Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon.

Authors:  D Tsambaos; D Eichelberg; M Goos
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

5.  Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study.

Authors:  Christoph M E Deuter; Ina Koetter; Ilhan Guenaydin; Nicole Stuebiger; Manfred Zierhut
Journal:  Retina       Date:  2006-09       Impact factor: 4.256

6.  Interferon-alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro.

Authors:  M C Gillies; T Su
Journal:  Microvasc Res       Date:  1995-05       Impact factor: 3.514

Review 7.  The use of interferon alpha in Behçet disease: review of the literature.

Authors:  Ina Kötter; Ilhan Günaydin; Manfred Zierhut; Nicole Stübiger
Journal:  Semin Arthritis Rheum       Date:  2004-04       Impact factor: 5.532

Review 8.  Cytokine gene therapy for malignant glioma.

Authors:  Hideho Okada; Ian F Pollack
Journal:  Expert Opin Biol Ther       Date:  2004-10       Impact factor: 4.388

9.  Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.

Authors:  Lothar Krause; Andreas Altenburg; Uwe Pleyer; Anne-Katrin Köhler; Christos C Zouboulis; Michael H Foerster
Journal:  J Rheumatol       Date:  2008-04-15       Impact factor: 4.666

Review 10.  The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects.

Authors:  S Mishima; K Masuda; Y Izawa; M Mochizuki; K Namba
Journal:  Trans Am Ophthalmol Soc       Date:  1979
View more
  1 in total

Review 1.  [Treatment of posterior noninfectious uveitis : Current situation and future developments].

Authors:  U Pleyer; D Pohlmann; N Stübiger
Journal:  Ophthalmologe       Date:  2016-05       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.